Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis

Antonino Catanzaro1*, Timothy C. Rodwell1, Donald G. Catanzaro2, Richard S. Garfein1, Roberta L. Jackson1, Marva Seifert1, Sophia B. Georgiou1, Andre Trollip3, Erik Groessl1, Naomi Hillery1, Valeriu Crudu4, Thomas C. Victor5, Camilla Rodrigues6, Grace Shou-Yean Lin6, Faramarz Valafar7, Edward Desmond6, Kathleen Eisenach8

1 University of California San Diego, La Jolla, California, United States of America, 2 University of Arkansas, Fayetteville, Arkansas, United States of America, 3 Stellenbosch University, Stellenbosch, South Africa, 4 Institute of Phthisiopneumology, Chisinau, Moldova, 5 PD Hinduja Hospital and Medical Research Centre, Mumbai, India, 6 Microbial Diseases Laboratory, California Department of Public Health, Richmond, California, United States of America, 7 San Diego State University, San Diego, California, United States of America, 8 University of Arkansas, Little Rock, Arkansas, United States of America

* acatanzaro@mail.ucsd.edu

Abstract

Background

The aim of this study was to compare the performance of several recently developed assays for the detection of multi- and extensively drug-resistant tuberculosis (M/XDR-TB) in a large, multinational field trial.

Methods

Samples from 1,128 M/XDR-TB suspects were examined by Line Probe Assay (LPA), Pyrosequencing (PSQ), and Microscopic Observation of Drug Susceptibility (MODS) and compared to the BACTEC MGIT960 reference standard to detect M/XDR-TB directly from patient sputum samples collected at TB clinics in India, Moldova, and South Africa.

Results

Specificity for all three assays was excellent: 97–100% for isoniazid (INH), rifampin (RIF), moxifloxacin (MOX) and ofloxacin (OFX) and 99–100% for amikacin (AMK), capreomycin (CAP) and kanamycin (KAN) resistance. Sensitivities were lower, but still very good: 94–100% for INH, RIF, MOX and OFX, and 84–90% for AMK and CAP, but only 48–62% for KAN.

In terms of agreement, statistically significant differences were only found for detection of RIF (MODS outperformed PSQ) and KAN (MODS outperformed LPA and PSQ) resistance. Mean time-to-result was 1.1 days for LPA and PSQ, 14.3 days for MODS, and 24.7 days for MGIT.

Conclusions

All three rapid assays evaluated provide clinicians with timely detection of resistance to the drugs tested; with molecular results available one day following laboratory receipt of
samples. In particular, the very high specificity seen for detection of drug resistance means that clinicians can use the results of these rapid tests to avoid the use of toxic drugs to which the infecting organism is resistant and develop treatment regiments that have a higher likelihood of yielding a successful outcome.

Introduction

In 2013, the World Health Organization (WHO) estimated that less than half of all drug-resistant tuberculosis (DR-TB) cases were detected globally [1]. Undetected resistance results in treatment failure and increases the risk of TB transmission and patient mortality [2–4]. The lack of available, globally approved diagnostic platforms capable of rapidly detecting multi- and extensively drug-resistant TB (M/XDR-TB) remains a critical gap. MDR-TB is defined as TB resistant to both isoniazid (INH) and rifampin (RIF) while XDR-TB is MDR-TB with additional resistance to any fluoroquinolone, including moxifloxacin (MOX) or ofloxacin (OFX), and one or more of the injectables: amikacin (AMK), kanamycin (KAN), or capreomycin (CAP).

Recognizing that rapid, accurate drug susceptibility testing (DST) is critical for effectively treating and halting transmission of DR-TB [5, 6], clinical and laboratory partners in India, Moldova, the Philippines, Peru, South Africa, and the United States formed the Global Consortium for Drug-resistant TB Diagnostics (GCDD, S1 Text) to develop, test, and improve rapid TB diagnostic assays for M/XDR-TB [7–10].

Line Probe Assays (LPAs) MTBDRplus and MTBDRsl (Hain Lifescience, Nehren, Germany) detect resistance to INH, RIF, MOX, OFX, AMK, KAN, CAP and ethambutol through DNA amplification and oligonucleotide probe hybridization to resistance-conferring regions of the \textit{Mtb} genome [11]. While version 1 of MTBDRplus was recommended by the WHO for the diagnosis of MDR-TB in 2008, the recently released version 2 has not been extensively studied [12,13]. The MTBDRsl LPA underwent WHO Expert Panel Review in 2013, but was not recommended as a replacement test for phenotypic DST for lack of sufficient performance data [14]. Pyrosequencing (PSQ) is a rapid sequencing technique used in several commercially available platforms; however, it is still under development for use as a TB diagnostic [8,15,16]. Our noncommercial PSQ M/XDR-TB assay involves sequencing and interpreting targeted, resistance-conferring regions of the \textit{Mtb} genome. PSQ has shown high sensitivity and specificity for detection of M/XDR-TB isolates in controlled laboratory settings, but has not been evaluated in a large clinical trial [17,18]. Microscopic Observation of Drug Susceptibility (MODS) is a noncommercial assay where drug-containing wells are inoculated directly with concentrated sputum and subsequent \textit{Mtb} growth is observed microscopically [19]. MODS has demonstrated high sensitivity and specificity for INH and RIF [20]. This study is the first large-scale clinical evaluation of extended MODS for XDR-TB.

Methods

Overview

Following Standards for the Reporting of Diagnostic Accuracy Studies (STARD), we completed a multicenter, prospective, head-to-head clinical evaluation study to compare the performance and speed of LPA, PSQ, and MODS for diagnosing drug resistance in patients at risk for M/ XDR-TB, relative to the WHO approved phenotypic reference standard of MGIT DST [21,22].
Clinical sites for the study included P.D. Hinduja National Hospital in Mumbai, India, the Phtisiopneumology Institute in Chisinau, Moldova, and multiple primary care clinics in Port Elizabeth, South Africa in collaboration with Stellenbosch University. Patients were treated at both public and private hospitals and clinics depending on study site. Our study, registered with ClinicalTrials.gov (#NCT02170441), was reviewed and approved by institutional review boards at University of California, San Diego and each of the study sites. All participants provided written informed consent. Participation did not alter the standard of care. To ensure procedures were standardized across all sites, a comprehensive validation process for laboratory and data collection procedures was completed prior to enrollment at all sites [7].

Enrollment and Sputum Collection
Patients presenting with risk factors for drug-resistant TB, who were known to be acid-fast bacilli (AFB) smear positive, or GeneXpert Mtb positive within the prior 14 days, and were age five or older were invited to participate. Frequency and patterns of recruitment were sequential but allowed to vary by site to accommodate individual site capacity. Two samples, one collected at enrollment and a second collected by the participant the following morning, were pooled and used for testing after decontamination and concentration by NALC-NaOH method [23].

Standard Drug Susceptibility Testing (DST)
DST for all Mtb culture positive specimens were performed with the MGIT system using manufacturer recommended methods and published WHO-recommended critical drug concentrations: INH 0.1, RIF 1.0, MOX 0.25, OFX 2.0, AMK 1.0, KAN 2.5, and CAP 2.5 (µg/ml) [24,25].

Rapid Diagnostic Assays
The LPAs used for this study were the GenoType MTBDRplus version 2 for detecting INH and RIF resistance and the GenoType MTBDRsl version 1 for MOX, OFX, AMK, KAN, and CAP resistance, performed following Hain manufacturer instructions [26,27]. LPA assays were performed on the sputum samples after they were decontaminated and concentrated as described above and were not repeated if results were uninterpretable or indeterminate.

The PSQ platform and methods used for this study have been detailed previously [8]. Briefly, PCR was performed to amplify targeted sequences using DNA extracted from decontaminated and concentrated sputum; PyroMark Q96ID system was used to generate sequencing data. Then, PyroMark IdentiFire software was used to align generated sequences to our library of wild type and mutant sequences. The gene target IS6110 identified Mtb, while targets used for detection of drug resistance included: katG, inhA promoter, and ahpC promoter for INH; rpoB for RIF; gyrA for MOX and OFX; and rrs for AMK, KAN, and CAP [8,28]. If PSQ failed for one or more targets for any isolate, those targets were repeated in duplicate. Results of the repeated reactions were considered only if one or both of the results yielded a 100% match with the sequencing library. If initial failures did not resolve upon re-testing, PSQ results were considered indeterminate.

The MODS test was performed as previously described using standard drug concentrations: INH 0.4, RIF 1.0, MOX 0.5, OFX 1.0, AMK 2.0, and KAN 5.0 (µg/ml) [10,29]. Preliminary studies did not result in a decisive critical concentration for CAP, so multiple concentrations, 1.25, 2.5, 5.0, and 10.0 (µg/ml), were used in the study, but a critical concentration of 2.5 µg/ml was used for this analysis [10]. The MODS test was not repeated in the event of indeterminate results since when the indeterminate result was observed the original specimen was no longer available.
Methods of data monitoring, reporting, and collation for this study have been described previously [7]. The supporting information files contain the optimal data set underlying the findings of this study, with all additional data available upon request.

Statistical Analysis

Using MGIT DST as a reference standard, sensitivity, specificity, positive/negative predictive values, and positive/negative likelihood ratios were calculated for each drug and rapid diagnostic test combination that produced interpretable results.

Discrepant cases between the MGIT reference standard and the three rapid assays were statistically tested using the Cochran's Q test which tests for differences in binary responses between three or more matched sets of frequencies or proportions [30]. To investigate the interpretability of the rapid test results (with respect to MGIT reference standard), each participant’s rapid assay results were coded 'success' (when the rapid test read Resistant or Susceptible and so did MGIT) or 'failure' (when the rapid test read Failure/Indeterminate and MGIT was Resistant or Susceptible). If significant differences (p < 0.05) were found, at least one rapid test had a different proportion of interpretable results than the others (with respect to the MGIT standard) thus we performed a post-hoc pairwise McNemar’s test to identify the nature of the difference.

To investigate the accuracy of rapid test results (with respect to MGIT reference standard), each participant’s rapid assay results were coded 'success' (when the rapid test read Resistant and so did the MGIT or the rapid test read Susceptible and so did MGIT) or 'failure' (when the rapid test disagreed with MGIT). If significant differences (p < 0.05) were found, at least one rapid test had a different accuracy than the others (with respect to the MGIT standard) thus we performed a post-hoc pairwise McNemar’s test to identify the nature of the difference.

Time-to-results (TTR) was examined for all assays that produced interpretable results. For the growth-based assays (MGIT and MODS), TTR was based on the entire period from sample processing through test completion. For the DNA-based assays (LPA and PSQ), TTR was calculated based on time for sample processing through DNA extraction and then PCR/test set up through completion, excluding time DNA was stored for batching.

Results

Patients

A total of 1181 patients were screened for the study; one participant was determined to be ineligible and 52 were withdrawn (mostly due to inability to produce sufficient sputum), resulting in a total of 1128 study participants (612 from India, 254 from Moldova, and 262 from South Africa). While all study participants were smear positive during the 14 days previous to enrollment, only 73% (826) of pooled sputa collected at enrollment were smear positive and 81% (914) of participants were culture positive for Mtb (Fig 1). The mean age of participants was 34 years (range: 8–79 years) and gender skewed male (64% vs. 36%) (Table 1). Most participants (74%) received at least one month of prior TB treatment and 47% were clinically failing treatment at time of enrollment. HIV test results were available for 73% of enrolled participants, and 19% of these were positive. South Africa had the highest rates of participants receiving >1 month of treatment for a prior TB episode (97%), and the highest rates of HIV positive participants (54%). Participants from Moldova had the highest rate of close contacts with known drug-resistant TB cases (78%). Thirty-three percent of the study population (n = 305) were susceptible to all seven study drugs, and half (50%) had MDR-TB. India had the highest proportion of participants with MDR-TB (68%) and XDR-TB (11%).
Fig 1. Flowchart of patient enrollment, clinical sample processing for Line Probe Assay (LPA), Microscopic Observation of Drug Susceptibility (MODS), and Pyrosequencing (PSQ) for seven anti-TB drugs: isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP). Includes one null PSQ sample result (denoted as ‘a’). R: Resistant, S: Susceptible, and I: Indeterminate. 

doi:10.1371/journal.pone.0136861.g001
### Table 1. Demographic, Clinical and Laboratory Characteristics of the Patients.

| Variable                                      | Value     | India       | Moldova     | South Africa | Total       |
|-----------------------------------------------|-----------|-------------|-------------|--------------|-------------|
| Number of patients—n                         | 612       | 254         | 262         | 1128         |             |
| Age, years—median (range)                    | 28 (8–78) | 41 (12–79)  | 38 (13–66)  | 34 (8–79)    |             |
| Gender—n (%)                                 |           |             |             |              |             |
| Male                                          | 329 (53.8)| 205 (80.7)  | 183 (69.9)  | 717 (63.6)   |             |
| Female                                        | 283 (46.2)| 49 (19.3)   | 79 (30.1)   | 411 (36.4)   |             |
| Ethnicity—n (%)                              |           |             |             |              |             |
| Hispanic                                      | 1 (0.2)   | 1 (0.4)     | -           | 2 (0.2)      |             |
| Non-Hispanic                                 | 611 (99.8)| 253 (99.6)  | 262 (100)   | 1126 (99.8)  |             |
| Race—n (%)                                   |           |             |             |              |             |
| White                                         | -         | 254 (100)   | 2 (0.8)     | 256 (22.7)   |             |
| Black                                         | -         | -           | 260 (99.2)  | 260 (23.0)   |             |
| Asian/Indian                                  | 612 (100) | -           | -           | 612 (54.3)   |             |
| Pacific Islander                             | -         | -           | -           | -            |             |
| Native American                               | -         | -           | -           | -            |             |
| Other                                         | -         | -           | -           | -            |             |
| HIV Status—n (%)                             |           |             |             |              |             |
| Positive                                      | 14 (2.3)  | 2 (0.8)     | 141 (53.8)  | 157 (13.9)   |             |
| Negative                                      | 310 (50.6)| 252 (99.2)  | 105 (40.1)  | 667 (59.1)   |             |
| Unavailable                                   | 288 (47.1)| -           | 16 (6.1)    | 304 (27.0)   |             |
| Screening Criteria                            |           |             |             |              |             |
| AFB smear+ within 14 days—n (%)               | Yes       | 612 (100)   | 254 (100)   | 262 (100)    | 1128 (100)  |
|                                               | No        | -           | -           | -            | -            |
| a) Previously received >1 month of treatment for a prior TB episode—n (%) | Yes | 526 (86.0) | 59 (23.2) | 254 (97.0) | 839 (74.4) |
|                                               | No        | 38 (6.2)    | 192 (75.6)  | 8 (3.0)      | 238 (21.1)  |
|                                               | Unknown   | 48 (7.8)    | 3 (1.2)     | -            | 51 (4.5)    |
| b) Failing standard TB treatment—n (%)        | Yes       | 487 (79.6)  | 16 (6.3)    | 25 (9.5)     | 528 (46.8)  |
|                                               | No        | 112 (18.3)  | 236 (92.9)  | 234 (89.3)   | 582 (51.6)  |
|                                               | Unknown   | 13 (2.1)    | 2 (0.8)     | 3 (1.2)      | 18 (1.6)    |
| c) Close contact with known drug-resistant TB case—n (%) | Yes | 169 (27.6) | 197 (77.5) | 29 (11.1) | 395 (35.0) |
|                                               | No        | 208 (34.0)  | 51 (20.1)   | 167 (63.7)   | 426 (37.8)  |
|                                               | Unknown   | 235 (38.4)  | 6 (2.4)     | 66 (25.2)    | 307 (27.2)  |
| d) Diagnosis with MDR-TB within last 30 days—n (%) | Yes | 141 (23.0) | 70 (27.6) | 26 (9.9) | 237 (21.0) |
|                                               | No        | 398 (65.0)  | 184 (72.4)  | 236 (90.1)   | 818 (72.5)  |
|                                               | Unknown   | 73 (12.0)   | -           | -            | 73 (6.5)    |
| e) Previously diagnosed with MDR-TB and are failing TB treatment | Yes | 240 (39.2) | 9 (3.5) | - | 249 (22.1) |
|                                               | No        | 179 (29.2)  | 245 (96.5)  | 262 (100)    | 686 (60.8)  |
|                                               | Unknown   | 193 (31.5)  | -           | -            | 193 (17.1)  |
| Patient Characteristics                       |           |             |             |              |             |
| Previous treatment for TB—n (%)               | Yes       | 312 (51.0)  | 60 (23.6)   | 248 (94.6)   | 620 (55.0)  |
|                                               | No        | 156 (25.5)  | 193 (76.0)  | 13 (5.0)     | 362 (32.1)  |
|                                               | Unknown   | 144 (23.5)  | 1 (0.4)     | 1 (0.4)      | 146 (12.9)  |
| If yes, number of prior TB episodes—mean, median (range) | 1.1,1 (0–5) | 1.4,1 (1–4) | 2.3,2 (0–10) | 1.6,2 (0–10) |             |
| Body Mass Index (BMI)—mean, median (range)    | 17.9,17.5 (9.0–32.9) | 20.4,19.9 (12.0–37.2) | 18.4,17.9 (7.0–32.4) | 18.6,18.3 (7.0–37.2) |             |
| HIV Status—n (%)                              |           |             |             |              |             |
| Positive                                      | 14 (2.3)  | 2 (0.8)     | 141 (53.8)  | 157 (13.9)   |             |
| Negative                                      | 310 (50.6)| 252 (99.2)  | 105 (40.1)  | 667 (59.1)   |             |
| Unavailable                                   | 288 (47.1)| -           | 16 (6.1)    | 304 (27.0)   |             |
| Laboratory Results                            |           |             |             |              |             |
| Standardized Results—n (%)                    |           |             |             |              |             |
| Smear +                                       | 511 (83.5)| 171 (67.3)  | 144 (55.0)  | 826 (73.2)   |             |
| Culture Positive                              | 492 (80.4)| 226 (89.0)  | 196 (74.8)  | 914 (81.0)   |             |

(Continued)
Sensitivity and Specificity

All three assays performed well for direct detection of INH and RIF resistance, with specificities ranging from 96% to 100% and sensitivities ranging from 94% to 100% (Fig 2, S1 Table). For direct detection of MOX and OFX resistance, specificities and sensitivities were high, 94% to 99% and 94% to 98%, respectively. For the detection of resistance to AMK or CAP specificity was also very high (almost 100%) while sensitivity was considerably lower (84%-90% for AMK and CAP and 48%-68% for KAN). The positive likelihood ratios of all three assays for all seven drugs were >20 and negative likelihood ratios were all ~0.1 or lower, with the exception of the assays detecting KAN resistance, which had somewhat higher negative likelihood ratios (0.38–0.52).

Comparative Assay Performance

The Cochran’s Q test demonstrated significant differences in the three tests’ ability to yield interpretable results for INH, RIF, AMK, KAN, and CAP, but not for OFX and MOX (Table 2 and S1 Table). For INH, LPA, and PSQ yielded significantly more interpretable results than MODS, while for RIF, LPA yielded significantly more interpretable results than MODS, which yielded significantly more interpretable results than PSQ. For the injectables (AMK, KAN, and CAP) PSQ yielded significantly more interpretable results than MODS, which yielded significantly more interpretable results than LPA (Table 2).

With regards to the ability of the assays to detect resistance as defined by MGIT DST, among isolates that produced an interpretable result for all rapid tests, significant differences were
evident only for the detection of RIF and KAN resistance. MODS detected significantly more RIF resistance compared to PSQ, and significantly more KAN resistance than both LPA and PSQ. All three tests had similar resistance detection capabilities for the remaining study drugs.

**Time to Result**

The mean TTR for phenotypic DST originating from MGIT culture was 24.7 days, from decontaminated MGIT culture was 40.5 days, and from LJ was 56.4 days (Fig 3). For the MODS assay, the average TTR was 14.3 days, while the MTBDR\textsubscript{plus} and MTBDR\textsubscript{sl} LPAs had an average TTR of 1.1 days. PSQ results were grouped into samples that gave valid results for all targets in a single run and those which required repeat runs of the assay to obtain a valid result for all drugs. A single PSQ run was sufficient to yield a valid result for all targets in an average of 0.6 days. For those samples requiring a second PSQ run to produce valid results, it took an average of 1.1 days to produce valid results.

**Discussion**

This study simultaneously assessed the performance of two DNA-based rapid diagnostic assays (LPA and PSQ) and one growth-based assay (MODS) to detect drug resistance in concentrated sputum specimens from 1,128 persons suspected of having M/XDR-TB. All three assays performed well among \textit{Mtb} culture positive specimens for detection of INH, RIF, MOX, and OFX resistance despite 16% smear negative patients and 12% HIV co-infection. Our experimental design (where every sample received every test) allowed us to statistically investigate

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|}
\hline
Drug & Interpretable Results & Agreement with MGIT DST \\
\hline
\hline
INH & $\chi^2 = 28.3$ & LPA*** & PSQ** $\rightarrow$ MODS & $\chi^2 = 0.70$ & N/A\textsuperscript{a} \\
 & p-value\textsuperscript{b} $< 0.001$ & p-value $= 0.070$ & \\
RIF & $\chi^2 = 96.7$ & LPA*** $\rightarrow$ MODS*** $\rightarrow$ PSQ & $\chi^2 = 16.9$ & MODS** $\rightarrow$ PSQ \\
 & p-value < 0.001 & p-value $< 0.001$ & \\
MOX & $\chi^2 = 2.0$ & N/A & $\chi^2 = 0.75$ & N/A \\
 & p-value = 0.37 & p-value $= 0.69$ & \\
OFX & $\chi^2 = 1.6$ & N/A & $\chi^2 = 1.6$ & N/A \\
 & p-value = 0.44 & p-value $= 0.46$ & \\
AMK & $\chi^2 = 77.9$ & PSQ*** $\rightarrow$ MODS*** $\rightarrow$ LPA & $\chi^2 = 2.0$ & N/A \\
 & p-value < 0.001 & p-value $= 0.37$ & \\
KAN & $\chi^2 = 77.9$ & PSQ*** $\rightarrow$ MODS*** $\rightarrow$ LPA & $\chi^2 = 16.7$ & MODS* $\rightarrow$ LPA & PSQ \\
 & p-value < 0.001 & p-value $< 0.001$ & \\
CAP & $\chi^2 = 77.9$ & PSQ*** $\rightarrow$ MODS*** $\rightarrow$ LPA & $\chi^2 = 1.0$ & N/A \\
 & p-value < 0.001 & p-value $= 0.61$ & \\
\hline
\end{tabular}
\caption{Comparison of the ability of three diagnostic assays to produce interpretable and results agreeing with MGIT drug susceptibility testing for isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP).}
\end{table}

\textsuperscript{a}Cochran’s Q test used to identify overall differences between assays for each drug.
\textsuperscript{b}McNemar pairwise comparisons test used to which assays differed significantly for each drug.
\textsuperscript{c}Pairwise comparisons were not performed if the Cochran’s Q test was not statistically significant (N/A).
\textsuperscript{d}P-values were continuity corrected for multiple comparisons using Bonferroni correction.

doi:10.1371/journal.pone.0136861.t002

\[p-value \leq 0.05\]
\[**p-value < 0.01\]
\[***p-value < 0.001\]
performance differences and determine that MTBDR\textit{plus} outperformed both PSQ and MODS for INH and RIF in ability to obtain interpretable results, even though sensitivity and specificity did not appear to be different from PSQ and MODS. As described in the Methods section, only samples that gave interpretable results by both MGIT and the rapid test of interest were used to calculate sensitivity and specificity, resulting in variation in the number of comparisons available for each assay and each antibiotic.

However, in terms of the second-line drugs AMK, KAN, and CAP, it is clear that PSQ produced more interpretable results than the other two tests even though all tests exhibited only moderate sensitivity for detection of AMK and CAP (84%) and poor sensitivity for KAN resistance (50%).

Together, MTBDR\textit{plus} and MTBDRs\textit{sl} LPAs comprise the only global, commercially available assays currently able to detect XDR-TB at the district hospital level or lower [14,31]. Our usage of the MTBDR\textit{plus} version 2 is the first large-scale clinical evaluation of the updated assay and our findings confirm that version 2 has similar performance for direct detection of RIF resistance as version 1 (97%/98% vs. WHO pooled sensitivity/specificity 98%/98%) [32]. However, we demonstrated a substantially higher sensitivity for INH resistance detection than the pooled sensitivity of the version 1 assay of 94% (95%CI 91, 96) vs. 84% (95%CI 77, 90) reported by the WHO Expert Panel [11,13].

---

**Fig 3. Time to Test Results (TTR).** Criteria for inclusion in the time-to-result calculations: tests worked for all drugs tested on the first attempt unless otherwise noted. Only results from the culture positive pooled (P1) samples were used. For the growth-based assays MGIT DST and MODS, TTR was the period from sample processing through test completion. For the genotypic tests, TTR was sample processing through DNA extraction and PCR/test set up through completion, excluding time DNA was stored for batching or lab convenience.

doi:10.1371/journal.pone.0136861.g003
In our study, MTBDR{sub}sl demonstrated substantially higher sensitivity for detection of MOX and OFX: 95% (95%CI: 91.8–97.6) compared to the WHO Expert Panel pooled sensitivity of 84% (95%CI: 61.9–91.0), but had comparable specificity of 99% vs. 97% reported by WHO [33]. Sensitivity of detection of AMK and CAP resistance were comparable to that documented by the WHO Expert Panel (87% vs. 86%) [33]. However, sensitivity for the detection of KAN resistance of 48% (95%CI: 38–58) was significantly below the WHO Expert Panel of 96% (95% CI: 67%-100%) [14]. This lower sensitivity was likely influenced by the high prevalence of eis promoter mutations at the Moldova study site [9], which are not detected by version 1.0 of the MTBDR{sub}sl assay. A new version of the assay including these eis promoter mutations, MTBDR{sub}sl version 2.0, is currently being evaluated, with a recent study finding an improved assay sensitivity of 86.4% in a multi-region study with 21.3% of injectable-resistant strains housing eis promoter mutations [34].

A major strength of the LPA assay is that it is currently commercially available in a kit form. Furthermore, while LPA is primarily a single sample test, it can be scaled-up to accommodate large numbers, and can produce results in a day. Limitations of LPA include the ratio of tests/interpretable results (S2 Table), the relatively high level skill required to run the assay (e.g. DNA processing), the comparatively high costs of the equipment compared to MODS, and the relative inflexibility of the assay to accommodate new mutations as knowledge of resistance-conferring mutations evolves.

In contrast to LPA, the major strength of the PSQ assay is its flexibility as an open sequencing technology, which allows for extensive post-processing analyses based on evolving knowledge, and its rapid adaptability to new mutations. The platform we evaluated in this study is one of the only XDR-TB diagnostics certified by Clinical Laboratory Improvement Amendments in the US, and this is the first large-scale clinical evaluation of the platform on direct sputum samples. The ability of PSQ to detect resistance to AMK, KAN, and CAP was superior compared to LPA and MODS, and was comparable to LPA for detection of INH, MOX, and OFX resistance, but had over twice the number of indeterminate results for the RIF resistance target—due mostly to amplification failures of the rpoB target. Given that both LPA and PSQ interrogate similar rpoB mutations, this suggests that further optimization of the PSQ rpoB amplification primers might improve performance.

Our previous studies of resistance-conferring mutations within rrs predicted that assays such as PSQ, capable of detecting the rrs 1401 mutation, should have approximately 88% sensitivity for detection of AMK and CAP resistance and 69% for KAN [9]. While reported sensitivities for AMK and CAP were both within 95% CI of our predictions (84%; 73–91% CI), reported sensitivities for KAN (50%; 41–60% CI) were lower than predicted. Preliminary, post study sequencing analysis of these isolates (data not shown) indicates that low KAN sensitivity was likely due to mutations within the eis promoter region that were not detected the PSQ assay. Future iterations of the platform will include detection of eis promoter and additional rrs mutations, which should increase sensitivity to AMK, KAN and CAP. Specificity of the assay for all targets was excellent and should increase confidence in the use of DNA-based diagnostics such as PSQ and LPA for ruling-in resistance to AMK, KAN and CAP. Limitations of the current PSQ platform include the need for high-level technical skills for handling of the complex, costly PSQ equipment, and a multi-step sequencing and analysis process. An integrated, tabletop PSQ platform is currently in development.

Our study is the first large evaluation of an XDR-TB MODS assay and we found it to be a highly sensitive and specific means of detecting INH, RIF, MOX, and OFX resistance direct from sputum and a moderately sensitive, highly specific means for detecting AMK and CAP resistance. MODS sensitivity for detection of KAN resistance was poor (62%), but MODS performed significantly better than both LPA and PSQ in terms of detecting KAN resistance,
largely due to the fact that neither the LPA nor the PSQ assay included detection of eis mutations which are now well known to confer a significant proportion of phenotypic KAN resistance in Mtb, especially in places like Moldova where a large proportion of KAN resistance was observed in our study. Next generation versions of both the Hain LPA and PSQ assays now include eis mutations which should considerably improve the detection of phenotypic KAN resistance by these assays.

The reason for the low MODS sensitivity observed for the detection of KAN resistance was less clear. Our decision to use 5μg/ml in the MODS assay as the critical concentration for KAN resistance was made based on extensive breakpoint optimization studies [10], but this critical concentration is substantially higher than the WHO’s most recently recommended critical concentration for phenotypic KAN DST (2.5μg/ml) on MGIT960 [24]. Like MODS, MGIT DST is based on a liquid culture method, and this reliance upon different critical concentrations when using the two growth-based technologies could help explain the low sensitivity we observed. While there are reasons to support the use of different optimal critical concentrations between the MODS and MGIT960 (as the two technologies use different methods), our data suggests revising the MODS critical concentration for KAN downward towards the concentration recommended for MGIT960.

The major strengths of the MODS assay is that it is a rapid (10 days quicker than MGIT DST), cheap, non-commercial assay that can be used to detect M/XDR-TB directly from processed sputum with inexpensive, readily purchased supplies or commercial kits [19,35–37]. Concerns over biohazard risk associated with daily readings of MODS have been eliminated by modifying the procedure to seal plates after inoculation to contain the infectious organisms. Finally, additional implementation considerations include MODS’s logistical requirements, which could limit the assays utility in high-throughput environments.

In conclusion, we have demonstrated that three existing technologies have very good to excellent sensitivity and specificity for the detection of resistance to the highest priority antibiotics used for TB: RIF, INH, MOX, and OFX. The observed differences in test performance by antibiotic may be the result of differences in primers used in the two gene based tests and concentrations of antibiotics used as cut off points in the two growth based tests. Additionally, each technology has limitations which likely confine them to use at the district, sub-district hospital level in their current forms.

Rapid initiation of treatment with a set of drugs to which Mtb is susceptible remains the most successful intervention in preventing the spread of M/XDR-TB and improving patient outcomes. Each of the three rapid DST assays we examined have major advantages over the MGIT in terms of saving weeks to months for the identification of drugs to which the organism is resistant while maintaining acceptable test performance. In particular, the very high specificity of detection of drug resistance means that clinicians can use the results of these rapid tests to avoid the use of toxic drugs to which the infecting organism is resistant and develop treatment regimens that have a higher likelihood of yielding a successful outcome. The availability of this information within a few hours of testing allows clinicians to quickly find effective treatment regimens and put a stop to the transmission of drug-resistant TB. These data suggest that the current recommendation for the initial treatment of active TB in areas of high rates of drug resistance can be improved by the use of rapid DST early in the treatment regimen. The very high specificity of the rapid identification of resistance to the drugs studied means that when resistance is identified one can to avoid the use of drugs that will not be efficacious but may increase toxicity. This strategy may decrease the infectious period, reduce treatment failure and may decrease defaults while reducing costs.
Supporting Information

S1 Dataset. GCDD Dataset.
(TXT)

S1 Table. Rapid Assay Performance. Agreement between three rapid tests and reference standard MGIT for detection of resistance for isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) Mtb culture positive specimens.
(DOCX)

S2 Table. Interpretable Results. Proportion of Mtb culture positive specimens for which interpretable results were produced by three diagnostic platforms with the ability to detect resistance to isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP).
(DOCX)

S1 Text. GCDD Contributors.
(DOCX)

Author Contributions

Conceived and designed the experiments: AC TCR DGC VC TCV CR. Performed the experiments: AT VC TCV CR. Analyzed the data: AC TCR DGC RLJ MS SBG EG NH. Contributed reagents/materials/analysis tools: AC TCR DGC RLJ MS EG NH FV. Wrote the paper: AC TCR DGC RLJ. Provided oversight to GCDD: AC TCR RG. Provided microbiological expertise: GSYL KE SBG RL ED.

References

1. WHO. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization, 2014 2014. Report No.
2. Institute of Medicine (US). Ending Neglect: The Elimination of Tuberculosis in the United States. Geiter L, editor. Washington (DC): National Academy Press (US); 2000.
3. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PloS one. 2010; 5(12): e15735. Epub 2011/01/07. doi:10.1371/journal.pone.0015735 PMID: 21209951
4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine. 2003; 167(4):603–62. PMID: 12588714
5. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. The international journal of Tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(10):1233–43.
6. Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. The international journal of Tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014; 18(9):1019–25.
7. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, et al. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): Design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials. 2014;Manuscript accepted for publication.
8. Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol. 2014; 52(2):475–82. Epub 2014/01/31. doi: 10.1128/JCM.01821-13 PMID: 24478476
9. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. Journal of clinical microbiology. 2014; 52(3):781–9. Epub 2013/12/20. doi:10.1128/JCM.02701-13 PMID: 24353002

10. Trollip AP, Moore D, Coronel J, Caviedes L, Klages S, Victor T, et al. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014; 18(2):227–32. Epub 2014/01/17.

11. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. The European respiratory journal. 2008; 32(5):1165–74. Epub 2008/07/11. doi: 10.1183/09031936.00061808 PMID: 18614561

12. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. Journal of clinical microbiology. 2012; 50(11):3712–6. Epub 2012/09/14. doi: 10.1128/JCM.01958-12 PMID: 22972826

13. WHO. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 2008.

14. WHO. WHO policy statement: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. Geneva, Switzerland: World Health Organization, 2013.

15. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. Journal of clinical microbiology. 2006; 44(6):1925–9. PMID:16757581

16. Marttila HJ, Makinen J, Marjamaki M, Soini H. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2009; 28(1):33–8.

17. Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, et al. Evaluation of Pyrosequencing for Detecting Extensively Drug-resistant Tuberculosis (XDR-TB) in Clinical Isolates from Four High-burden Countries. Antimicrob Agents Chemother. 2015. Epub 3 November 2014.

18. Engstrom A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. Journal of clinical microbiology. 2012; 50(6):2026–33. Epub 2012/03/31. doi: 10.1128/JCM.06664-11 PMID: 22461677

19. Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. Journal of clinical microbiology. 2000; 38(3):1203–8. PMID:10699023

20. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. The New England journal of medicine. 2006; 355 (15):1539–50. PMID: 17035648

21. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of rifampin and isoniazid resistance. The New England journal of medicine. 2010; 363(11):1005–15. doi: 10.1056/NEJMoa0907847 PMID: 20825313

22. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clinical chemistry. 2003; 49(1):1–6. PMID: 12507953

23. Kent PT, Kubic G, Centers for Disease Control (U.S.). Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Ga.: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control; 1985. viii, 207 p. p.

24. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2008; 12(12):1449–51.

25. WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva, Switzerland: World Health Organization, 2008.

26. Lifescience H. GenoType MTBDRsl ver 1.0: instruction manual. Nehren, Germany: Hain Lifescience GmbH, 2009.

27. Lifescience H. GenoType MTBDRplus ver 2.0: instruction manual. Nehren, Germany: Hain Lifescience GmbH, 2012.
28. Bravo LT, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. Journal of clinical microbiology. 2009; 47(12):3985–90. doi: 10.1128/JCM.01229-09 PMID: 19846642
29. Park WG, Bishai WR, Chaisson RE, Dorman SE. Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. Journal of clinical microbiology. 2002; 40(12):4750–2. PMID: 12454186
30. Ilstrup DM. Statistical methods in microbiology. Clin Microbiol Rev. 1990; 3:219–26. PMID: 2200604
31. Dixit P, Singh U, Sharma P, Jain A. Evaluation of nitrate reduction assay, resazurin microtiter assay and microscopic observation drug susceptibility assay for first line antitubercular drug susceptibility testing of clinical isolates of M. tuberculosis. Journal of microbiological methods. 2012; 88(1):122–6. doi: 10.1016/j.mimet.2011.11.006 PMID: 22133919
32. WHO. Expert Group Report: Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multi-drug Resistant Tuberculosis. 2008.
33. Huang Z, Li G, Chen J, Li W, Xu X, Luo Q, et al. Evaluation of MODS assay for rapid detection of Mycobacterium tuberculosis resistance to second-line drugs in a tertiary care tuberculosis hospital in China. Tuberculosis. 2014; 94(5):506–10. doi: 10.1016/j.tube.2014.06.005 PMID: 25082461
34. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, et al. Diagnostic Performance of the new version of GenoType MTBDRs (V2.0) Assay for detection of resistance to Fluoroquinolones and Second Line Injectable Drugs: a Multicenter study. Journal of Clinical Microbiology. 2015; doi: 10.1128/JCM.01257-15
35. Huang ZK, Luo Q, Xiong GL, Li WT, Xu XM, Li JM. Evaluation of indirect drug susceptibility testing using the MODS assay for the detection of XDR-TB in China. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014; 18(4):461–5.
36. Martin L, Coronel J, Faulx D, Valdez M, Metzler M, Crudder C, et al. A field evaluation of the Hardy TB MODS Kit for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis. PloS one. 2014; 9(9):e107258. doi: 10.1371/journal.pone.0107258 PMID: 25225802
37. Makamure B, Mhaka J, Makumbirofa S, Mutetwa R, Mpfumi L, Mason P, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, Zimbabwe. PloS one. 2013; 8(2):e5587